Latest Breaking News On - Immunovant inc - Page 13 : comparemela.com

Insider Selling: Immunovant, Inc (NASDAQ:IMVT) Insider Sells 1,297 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Julia G. Butchko sold 1,297 shares of Immunovant stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $38.59, for a total value of $50,051.23. Following the sale, the insider now owns 409,963 shares in the company, valued at approximately […]

New zealand generalNew zealandJuliag butchkoPiper sandlerDeutsche bank aktiengesellschaftWellington management groupImmunovant incSecurities exchange commissionComerica bankCitigroup incVanguard group incManufacturers life insurance companyGet free reportExchange commissionBank aktiengesellschaftManagement group

Brokerages Set Immunovant, Inc (NASDAQ:IMVT) Target Price at $45 07

Brokerages Set Immunovant, Inc (NASDAQ:IMVT) Target Price at $45 07
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Raymond jamesMarks levinePeter salzmannImmunovant company profileJpmorgan chase coBlackrock incImmunovant incMetlife investment managementSwiss national bankDimensional fund advisorsDeutsche bank aktiengesellschaftGet free reportMarketbeat ratingsBank aktiengesellschaftNational bankLife investment management

Bailard Inc Takes Position in Immunovant, Inc (NASDAQ:IMVT)

Bailard Inc Takes Position in Immunovant, Inc (NASDAQ:IMVT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Eva renee barnettPiper sandlerPeter salzmannRaymond jamesBarclays plcLife insurance coWells fargo companyAllspring global investments holdingsImmunovant incBailard incAmeritas investment partners incExchange commissionSecurities exchange commissionFree reportGlobal investments holdingsAmeritas investment partners

Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A

Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A
themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesBrad loncarRob davisNick shipleyMike gaitoEric tokatJapan daiichi sankyo coSeagen incKaruna therapeutics incJpmorgan chase coMerck coImmunovant incPrometheus biosciences incGilead sciences incRoche holding

Ozempic challengers, immunology firms line up for rebound in M&A

Biotech investors are heading into the year s biggest dealmaking event with a renewed sense of optimism after more than two years of layoffs and shrin.

San franciscoUnited statesNick shipleyEric tokatBrad loncarRob davisMike gaitoBristol myers squibb coRoche holdingPrometheus biosciences incImmunovant incPfizer incKaruna therapeutics incCarmot therapeutics incAbbvie incImmunogen inc